ROIV Share Price Performance
US$40.82
26.87 (192.62%)
2.4% undervalued intrinsic discount
US$41.82
Fair Value
Price US$40.82
AnalystConsensusTarget US$41.82
AnalystLowTarget US$31.50
AnimalDoctorKwon US$10.00
Fair ValueUS$41.82
Share Pricen/a
Roivant Sciences Ltd. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
ROIV Community Narratives
AN
Fair Value
·Fair Value US$41.82 2.4% undervalued intrinsic discount
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value
·Fair Value US$31.5 29.6% overvalued intrinsic discount
Autoimmune Pipeline And Late Stage Blockbusters Will Face Relentless Competition And Margin Pressure
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$10 308.2% overvalued intrinsic discount
overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Roivant Sciences
308.2% overvalued intrinsic discount
overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
View narrativeAN
Published 19 Jul
Roivant Sciences
2.4% undervalued intrinsic discount
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
View narrativeAN
Updated 17 Aug
Roivant Sciences
15.8% undervalued intrinsic discount
Late Stage Autoimmune Pipeline Will Unlock Transformational Long Term Upside
View narrativeAN
Updated 3 Sep
Roivant Sciences
29.6% overvalued intrinsic discount
Autoimmune Pipeline And Late Stage Blockbusters Will Face Relentless Competition And Margin Pressure
View narrativeAN
Updated 20 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
Fair Value: US$10 308.2% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ROIV: Late Stage Dermatomyositis Milestones Will Drive Future Upside Potential
Fair Value: US$48.46 15.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ROIV: 2026 Autoimmune And Cardiopulmonary Readouts Will Drive Bullish Repricing
Fair Value: US$41.82 2.4% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Roivant Sciences Ltd. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.37
- -9,610.89%
- -3,534.96%
- 0%
About ROIV
- Founded
- 2014
- Employees
- 721
- CEO
- WebsiteView website
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
